Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (NASDAQ:SAGE) on Sunday, setting a price target of $100, which is approximately 75.81% above the present share price of $56.88.
Olson expects SAGE Therapeutics to post earnings per share (EPS) of -$1.64 for the second quarter of 2021.
The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in SAGE Therapeutics, with an average price target of $90.72.
The analysts price targets range from a high of $189 to a low of $60.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $1.58 million and a net profit of -$96.51 million. The company's market cap is $3.33 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.3% and a 49.72% success rate.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.